Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Esmeralda van der Helm"'
Autor:
Nadine C Salisch, Marija Vujadinovic, Esmeralda van der Helm, Dirk Spek, Lars Vorthoren, Jan Serroyen, Harmjan Kuipers, Hanneke Schuitemaker, Roland Zahn, Jerome Custers, Jort Vellinga
Publikováno v:
PLoS ONE, Vol 12, Iss 3, p e0174728 (2017)
Durable protection against complex pathogens is likely to require immunity that comprises both humoral and cellular responses. While heterologous prime-boost regimens based on recombinant, replication-incompetent Adenoviral vectors (AdV) and adjuvant
Externí odkaz:
https://doaj.org/article/3733e047edd84080b2345657bb77a65b
Autor:
Roland Zahn, Gert Gillisen, Anna Roos, Marina Koning, Esmeralda van der Helm, Dirk Spek, Mo Weijtens, Maria Grazia Pau, Katarina Radošević, Gerrit Jan Weverling, Jerome Custers, Jort Vellinga, Hanneke Schuitemaker, Jaap Goudsmit, Ariane Rodríguez
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e44115 (2012)
Filoviruses cause sporadic but highly lethal outbreaks of hemorrhagic fever in Africa in the human population. Currently, no drug or vaccine is available for treatment or prevention. A previous study with a vaccine candidate based on the low seroprev
Externí odkaz:
https://doaj.org/article/b7bb292de4504790b301e18796ccd435
Autor:
Mark Vermeulen, Esmeralda van der Helm, Jort Vellinga, Benoit Christophe Stephan Callendret, Marina Koning, Jan Serroyen, Maria Grazia Pau, Kerstin Wunderlich, Roland Zahn, Hanneke Schuitemaker, Dirk Spek, Adile Gecgel, Barbara Petronella Sanders, Jerome Custers, Marija Vujadinovic, Masha Stalknecht, Karin de Boer
Publikováno v:
Human gene therapy, 29(3), 337-351. Mary Ann Liebert Inc.
Genetic vaccines based on replication-incompetent adenoviral (AdV) vectors are currently in clinical development. Monovalent AdV vectors express one antigen from an expression cassette placed in most cases in the E1 region. For many vaccines, inclusi
Autor:
Roland Zahn, Jan Serroyen, Esmeralda van der Helm, Hanneke Schuitemaker, Jerome Custers, Marija Vujadinovic, Lars Vorthoren, Nadine C. Salisch, Harmjan Kuipers, Jort Vellinga, Dirk Spek
Publikováno v:
PLoS ONE, Vol 12, Iss 3, p e0174728 (2017)
PLoS ONE
PLoS ONE
Durable protection against complex pathogens is likely to require immunity that comprises both humoral and cellular responses. While heterologous prime-boost regimens based on recombinant, replication-incompetent Adenoviral vectors (AdV) and adjuvant
Autor:
Ton Logtenberg, Nathalie Kroos, Sven van der Kraats, Patrick Van Berkel, Dirk-Jan Opstelten, Shirley Smits, Abraham Bout, David Halford Ashton Jones, Andre Vooys, Bart A. Van Montfort, Regina Anema, Jan Schouten, Fija M. Lagerwerf, Kirsten Brouwer, Esmeralda van der Helm
Publikováno v:
Biotechnology Progress. 19:163-168
The number of therapeutic monoclonal antibodies in production is expected to rise rapidly in the next few years. As a result, there is much focus on the optimization of antibody expression platforms. Several issues are important including the speed o
Autor:
Mark Vermeulen, Adile Gecgel, Maria Grazia Pau, Esmeralda van der Helm, Jerome Custers, Dirk Spek, Jort Vellinga, Kerstin Wunderlich
Publikováno v:
The Journal of general virology. 95(Pt 7)
During the development of human adenovirus 35-derived replication-incompetent (rAd35) vaccine vectors for prevention of infectious diseases, we detected mutations in the terminal 8 nt of the inverted terminal repeats (ITRs) of rAd35. The switch from
Autor:
Roland Zahn, Dirk Spek, Anna Roos, Jort Vellinga, Mo Weijtens, Katarina Radosevic, Maria Grazia Pau, Hanneke Schuitemaker, Gerrit Jan Weverling, Esmeralda van der Helm, Ariane Rodriguez, Jerome Custers, Marina Koning, Gert Gillisen, Jaap Goudsmit
Publikováno v:
PLoS ONE
PLoS ONE, Vol 7, Iss 12, p e44115 (2012)
PLoS ONE, 7(12). Public Library of Science
PLoS ONE, Vol 7, Iss 12, p e44115 (2012)
PLoS ONE, 7(12). Public Library of Science
Filoviruses cause sporadic but highly lethal outbreaks of hemorrhagic fever in Africa in the human population. Currently, no drug or vaccine is available for treatment or prevention. A previous study with a vaccine candidate based on the low seroprev
Autor:
Paul H.A. Quax, Menzo J. E. Havenga, Esmeralda van der Helm, Ben Berkhout, Jos M. Grimbergen, Jorn Kaspers, Ronald Vogels, Jerome Custers, Angelique A. C. Lemckert, Lennart Holterman, Sandra Verhaagh, Jaap Goudsmit, Margreet Bakker, Martijn Sieuwerts, Gert Gillissen, Eric Geelen, David Zuijdgeest, Remko Van Der Vlugt
Publikováno v:
Journal of virology, 78(23), 13207-13215. American Society for Microbiology
A novel plasmid-based adenovirus vector system that enables manufacturing of replication-incompetent (ΔE1) adenovirus type 11 (Ad11)-based vectors is described. Ad11 vectors are produced on PER.C6/55K cells yielding high-titer vector batches after p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d85ee8ac4a66698d59f389097eb281b
https://pure.amc.nl/en/publications/novel-replicationincompetent-vector-derived-from-adenovirus-type-11-ad11-for-vaccination-and-gene-therapy-low-seroprevalence-and-noncrossreactivity-with-ad5(2c3a610f-3333-49ce-a941-43ef4052dff9).html
https://pure.amc.nl/en/publications/novel-replicationincompetent-vector-derived-from-adenovirus-type-11-ad11-for-vaccination-and-gene-therapy-low-seroprevalence-and-noncrossreactivity-with-ad5(2c3a610f-3333-49ce-a941-43ef4052dff9).html